Landmark Study Reveals Over 20% of Cancer Patients Eligible for Pan-Cancer Therapies
• Caris Life Sciences published a groundbreaking study in Nature Communications analyzing over 295,000 cancer patients, revealing that more than 20% are eligible for tissue-agnostic "pan-cancer" therapies targeting specific molecular features rather than tumor location.
• The research uncovered significant variability in treatment efficacy across different cancer types, challenging the notion that tissue-agnostic therapies work equally well in all tumors and suggesting potential for expanding approvals to other drugs in the same class.
• Despite proven efficacy, the study found poor clinical uptake of tissue-agnostic therapies for rare indications, highlighting the need for enhanced physician education about these powerful treatment options.
Circulating DNA/RNA Market Set to Triple to $16.4 Billion by 2032, Driven by Patent Innovations
• The global circulating DNA/RNA market is projected to grow from $5.32 billion in 2023 to $16.4 billion by 2032, advancing at a CAGR of 13.29% according to a new patent landscape report.
• Key industry players Nantomics, Genentech, and Novartis are leading innovation in the sector, with the United States dominating patent activity with over 600 patents, followed by Europe and Asia.
• The oncology segment leads patent filings, with technological advancements in non-invasive diagnostics and personalized medicine driving market expansion and creating new opportunities in genomic medicine.
Global DNA Sequencing Market Set to Reach $106 Billion by 2034, Driven by Next-Generation Technologies
• The global DNA sequencing market is projected to grow from approximately $15 billion in 2024 to over $100 billion by 2034, with a CAGR of 14.9-21.7% according to market research firms.
• Next-generation sequencing (NGS) dominates the market with over 87% share, while oncology applications represent the largest segment at 25.5% of the total market.
• Technological advancements, reduced sequencing costs, and integration of artificial intelligence are accelerating adoption across clinical research, personalized medicine, and consumer genomics.
© Copyright 2025. All Rights Reserved by MedPath